- Home
- OACC vs CRDF Comparison
OACC vs CRDF Comparison
Compare OACC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OACC
- CRDF
- Stock Information
- Founded
- OACC 2024
- CRDF 1999
- Country
- OACC United States
- CRDF United States
- Employees
- OACC N/A
- CRDF N/A
- Industry
- OACC
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OACC
- CRDF Health Care
- Exchange
- OACC NYSE
- CRDF Nasdaq
- Market Cap
- OACC 256.3M
- CRDF 233.5M
- IPO Year
- OACC 2024
- CRDF N/A
- Fundamental
- Price
- OACC $10.47
- CRDF $3.97
- Analyst Decision
- OACC
- CRDF Strong Buy
- Analyst Count
- OACC 0
- CRDF 6
- Target Price
- OACC N/A
- CRDF $11.92
- AVG Volume (30 Days)
- OACC 25.5K
- CRDF 1.6M
- Earning Date
- OACC 01-01-0001
- CRDF 08-07-2025
- Dividend Yield
- OACC N/A
- CRDF N/A
- EPS Growth
- OACC N/A
- CRDF N/A
- EPS
- OACC N/A
- CRDF N/A
- Revenue
- OACC N/A
- CRDF $587,000.00
- Revenue This Year
- OACC N/A
- CRDF N/A
- Revenue Next Year
- OACC N/A
- CRDF N/A
- P/E Ratio
- OACC $96.64
- CRDF N/A
- Revenue Growth
- OACC N/A
- CRDF N/A
- 52 Week Low
- OACC $9.95
- CRDF $2.01
- 52 Week High
- OACC $10.85
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- OACC N/A
- CRDF 52.55
- Support Level
- OACC N/A
- CRDF $3.73
- Resistance Level
- OACC N/A
- CRDF $4.52
- Average True Range (ATR)
- OACC 0.00
- CRDF 0.30
- MACD
- OACC 0.00
- CRDF -0.02
- Stochastic Oscillator
- OACC 0.00
- CRDF 30.59
About OACC OAKTREE ACQUISITION CORP III LIFE S
Oaktree Acquisition Corp III Life Sciences is a blank check company.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.